Meta-analysis suggests idarucizumab-enabled thrombolysis is feasible for dabigatran-treated stroke patients after AF ablation.
Reversing blood thinners may allow stroke treatment with good safety and recovery.
This meta-analysis and case report review examines idarucizumab-enabled intravenous thrombolysis in dabigatran-treated patients with peripro…
Reversing dabigatran before stroke treatment appears safe, showing low bleeding and death rates with recovery similar to standard care.
Meta-analysis models cost-effectiveness of IV alteplase plus thrombectomy for large vessel occlusion stroke.
Adding alteplase to stroke surgery is cost-effective when treatment starts within 170 minutes.
This meta-analysis models cost-effectiveness using individual patient data from 6 trials involving 2,268 patients across 16 countries. It ev…
Adding clot-busting medicine to stroke surgery saves money and improves value when treatment starts within 170 minutes, but benefits fade af…
Cortical Superficial Siderosis Burden Predicts Hemorrhage and Poor Outcomes After Stroke Thrombolysis
New Brain Scan Marker Predicts Bleeding Risk Before Treatment
A substudy of the AcT trial (alteplase versus tenecteplase) evaluated radiological Boston CAA criteria and constituent markers in 482 thromb…
A specific brain scan pattern predicts dangerous bleeding after clot-busting drugs, helping doctors decide who needs fast treatment to save …
Marked hyperglycemia linked to higher parenchymal hematoma risk with bridging therapy versus direct EVT in stroke
High blood sugar linked to bleeding risk after stroke clot removal procedure
A post hoc analysis of 627 patients from the DIRECT-MT trial found that in those with admission glucose >11.1 mmol/L, bridging therapy (alte…
Very high blood sugar levels may increase bleeding risk for stroke patients who receive clot-busting drugs before mechanical clot removal.
Reteplase and non-immunogenic staphylokinase show superior functional outcomes vs alteplase in AIS within 4.5h
Which clot-busting drug works best for stroke? Two newer options may help more people walk and talk normally again.
A network meta-analysis of 21 RCTs (n=16,837) found reteplase (18+18 mg) and non-immunogenic recombinant staphylokinase (10 mg) were associa…
Two newer clot-busting drugs help more stroke patients walk and talk normally again without increasing the risk of dying within 90 days.